Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chugai Aims to Be No. 1 in Oncology, Nephrology, Bone/Joint Diseases: Mr Nagayama
February 21, 2011
- FDA Adds Actos to List of Drugs with Potential Signals of Serious Risk
February 21, 2011
- DSP to Enhance R&D in Oncology
February 21, 2011
- Sales of Ethical Drugs Down 0.8% in December 2010
February 21, 2011
- Eisai Ties Up with Teikoku Seiyaku for Transdermal Aricept Formulation in Japan
February 21, 2011
- Importance of Close Links between Clinical Trials, Studies Highlighted at Gene Therapy Symposium
February 21, 2011
- Medipal Aims at Sales of ¥3 Tril. in FY2013
February 21, 2011
- Look at New Trends in Emerging Countries: Mr Hasegawa
February 21, 2011
- Price Settlement Rate Down to Levels before Emergency Call
February 21, 2011
- Takeda Begins PIII Trial of Alogliptin in China
February 21, 2011
- New Drugs Improve Range of Options for Osteoporosis: 1
February 21, 2011
- Korosho to Carry Out Case Studies to Promote Use of Generics
February 21, 2011
- No Approach from Sawai Since December: Kyorin
February 14, 2011
- MTPC Found to Have Omitted Voluntary Stability Studies as Well
February 14, 2011
- Pharmarise Dispenses Increasing Number of Generics
February 14, 2011
- Quick Answer Required on Efficacy of Dasen
February 14, 2011
- Mr Urushibata to Resign as JPhA Councilor
February 14, 2011
- Initial Sales of Kissei's EPO Biosimilar Disappointing
February 14, 2011
- AZ to Apply for 4 NMEs by 2016 in Japan
February 14, 2011
- JPhA Calls on Members to Settle Prices by End of March
February 14, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…